Zura Bio Limited is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases. The company focuses on immune-mediated conditions with significant unmet medical need, utilizing a dual antagonism strategy to target multiple biological pathways simultaneously. Its pipeline consists of three in-licensed clinical-stage product candidates: tibulizumab (ZB-106), a humanized bispecific antibody targeting interleukin-17A and B cell activating factor; crebankitug (ZB-168), a monoclonal antibody targeting interleukin-7 receptor alpha; and torudokimab (ZB-880), a monoclonal antibody targeting interleukin-33. Zura Bio is currently conducting global Phase 2 clinical trials for tibulizumab in hidradenitis suppurativa and diffuse cutaneous systemic sclerosis. The company in-licensed crebankitug from Pfizer and torudokimab from Eli Lilly and Company, while tibulizumab was in-licensed from Eli Lilly and Company following earlier Phase 1 trials conducted by the latter. Zura Bio was founded as a limited company and completed a business combination with JATT Acquisition Corp. to advance its development programs.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage zurabio.com
Sector Healthcare IR page investors.zurabio.com
Tags
autoimmune diseases, inflammatory diseases, bispecific antibodies, monoclonal antibodies, immunology, clinical-stage, hidradenitis suppurativa, systemic sclerosis, cytokine inhibition, tibulizumab, ZB-106, crebankitug, ZB-168, torudokimab, ZB-880, TibuSHIELD, TibuSURE
Press page —

Metrics

Valuation  
Market cap $ 400.635M
Market cap (USD) $ 400.635M
P/E -3.71
PEG —
P/BV 2.26
P/S —
P/OCF -17.94
P/FCF -17.90
Dividend yield —
Turnover / mcap —
Returns  
ROE -55.3%
ROI -67.6%
ROIC -55.6%
Profit margin —
Growth  
Revenue growing —
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 2
Quality score -53.8%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022
Assets 113.948M 179.533M 100.843M 141.508M
Net profit -68.65M -52.403M -60.36M 3.549M
Free cash flow -64.928M -28.151M -23.054M -13.202M

Figure FY 2025 FY 2024 FY 2023 FY 2022
Share price 5.24 2.5 4.67 —
Price performance 12m 1.1 -0.46 — —

Filed figures

Figure Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Cash and deposits (USD) 729,223 13,785 99.8M 176M 109M
Cash flow detail
Operating cash flow (USD) — -1.07M -15.1M -28.1M -64.8M
Purchases of property, plant and equipment (USD) — — — -75,000 -113,000
Change in payables (cash effect) (USD) — 212,272 5.94M 4.21M -2.16M
Share-based compensation (USD) — 334,000 7.47M 16.8M 12.3M
Free cash flow (OCF - PPE - intangibles) (USD) — — — -28.2M -64.9M
Income detail
Research and development expense (USD) — 23.7M 44M 24.4M 42.1M
Reported Apr 11, 2022 Mar 28, 2024 Mar 28, 2024 Mar 25, 2025 Mar 19, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

November 9, 2026 7:00 AM

· Study did not meet primary endpoint of percentage change from baseline in total abscess and inflammatory nodule (AN) count at Week 16

· Key secondary endpoints, including HiSCR50 and HiSCR75, were not met

· Both doses of tibulizumab were well tolerated; observed safety was consistent with established safety profiles for both IL-17 and BAFF inhibition

· The ongoing TibuSURE trial in systemic sclerosis (SSc) and the planned NEXUS-PMR trial in polymyalgia rheumatica (PMR) will continue, with data expected in H1 2027 and Q4 2028, respectively; Zura is discontinuing development in hidradenitis suppurativa

HENDERSON, Nev.--(BUSINESS WIRE)--November 9, 2026-- Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced that its Phase 2 TibuSHIELD study, which evaluated tibulizumab (ZB-106) in adults with moderate-to-severe hidradenitis suppurativa (HS), did not meet its primary endpoint of percentage change from baseline in total abscess and inflammatory nodule (AN

October 27, 2026

PDF Version

  • TibuSHIELD topline data in hidradenitis suppurativa (HS) remains on track for Q4 2026; enrollment completed with 247 participants randomized, exceeding target

  • TibuSURE topline data in systemic sclerosis (SSc) remains on track for H1 2027; enrollment completed with 91 participants randomized, exceeding target

  • NEXUS-PMR, a Phase 2 study evaluating tibulizumab in polymyalgia rheumatica (PMR), remains on track to initiate by year-end 2026

  • Cash and cash equivalents of $187.7 million as of September 30, 2026, which is expected to fund planned operations through at least the end of 2028

HENDERSON, Nev.--(BUSINESS WIRE)--Oct. 27, 2026-- Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced financial results for the third quarter ended September 30, 2026, and provided recent corporate updates.

“Our team continues to execute efficiently on our development plan for tibulizumab, and we are excited as we enter this data-rich period for the company. We are on track to report topline results from our TibuSHIELD study in HS later this quarter, followed by topline results from our TibuSURE study in SSc in the first half of 2027,” said Sandeep Kulkarni, M.D., co-founder and Chief Executive Officer of Zura. “We continue to believe deeply in tibulizumab’s potential to address complex immune biology and unmet needs across indications, including in PMR, where we will be starting the NEXUS-PMR study by end of year. With cash runway sufficient to deliver results from all three studies, Zura is in a great position to deliver on tibulizumab’s unique potential.”

PROGRAM UPDATES

Tibulizumab (ZB-106)

Both ongoing Phase 2 studies of tibulizumab, a bispecific antibody designed to neutralize interleukin-17 (IL-17) and B-cell activating factor (BAFF), are fully enrolled and progressing toward topline data, and Zura also remains on track to initiate a Phase 2 study in PMR, the third indication for tibulizumab, by year-end 2026.

  • TibuSHIELD (HS): The Phase 2 clinical study evaluating tibulizumab in adults with hidradenitis suppurativa completed enrollment in June 2026 with 247 participants, exceeding its target. Topline data remains on track for the fourth quarter of 2026 and will include the primary endpoint, percent change from baseline in total abscess and inflammatory nodule count at Week 16, as well as the proportion of participants achieving HiSCR50 or HiSCR75.

  • TibuSURE (SSc): The Phase 2 clinical study evaluating tibulizumab in adults with early diffuse cutaneous systemic sclerosis completed enrollment in July 2026 with 91 participants, exceeding its target. Topline data remains on track for the first half of 2027 and will include the primary endpoint, change from baseline in modified Rodnan Skin Score (mRSS) at Week 24, as well as measures of lung involvement.

  • NEXUS-PMR (PMR): The Phase 2 clinical study evaluating tibulizumab in adults with polymyalgia rheumatica, an inflammatory disease in which most patients remain dependent on long-term glucocorticoids, has been cleared by the U.S. Food and Drug Administration (FDA) to proceed under an Investigational New Drug application and remains on track to initiate by year-end 2026.

Tibulizumab is an investigational compound and has not been approved for marketing by the FDA or any other regulatory authority.

Additional Clinical-Stage Product Candidates

In addition to tibulizumab, Zura is continuing its evaluation of potential development approaches for torudokimab (ZB-880) and crebankitug (ZB-168), informed by current clinical and translational evidence and ongoing assessment of the evolving competitive landscape.

THIRD QUARTER 2026 FINANCIAL RESULTS

Cash Position

As of September 30, 2026, Zura had cash and cash equivalents of $187.7 million. Zura expects that its existing cash and cash equivalents are sufficient to support planned operations through at least the end of 2028.

Research and Development (R&D) Expenses

R&D expenses were $19.5 million for the third quarter of 2026, compared to $11.9 million for the same period in 2025. The increase was primarily driven by the continued execution of Zura’s Phase 2 tibulizumab clinical programs as well as start-up activities for NEXUS-PMR.

General and Administrative (G&A) Expenses

G&A expenses were $9.3 million for the third quarter of 2026, compared to $7.6 million for the same period in 2025. The increase was primarily due to higher professional fees.

Net loss for the third quarter of 2026 was $25.8 million, or $0.20 per share, compared to $20.0 million, or $0.21 per share, for the same period in 2025.

ABOUT ZURA

Zura is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases with unmet need. Zura’s pipeline includes product candidates designed to target key mechanisms of immune system imbalance, with the goal of improving efficacy, safety, and dosing convenience for patients.

Zura’s lead product candidate, tibulizumab (ZB-106), is being evaluated in two Phase 2 clinical studies in adults: TibuSHIELD, a study in hidradenitis suppurativa (HS), and TibuSURE, a study in systemic sclerosis (SSc). A third Phase 2 clinical study in polymyalgia rheumatica (PMR), NEXUS-PMR, is planned to begin by year-end 2026. Additional product candidates torudokimab (ZB-880) and crebankitug (ZB-168) have completed Phase 1/1b studies and are being evaluated for their potential across a range of autoimmune and inflammatory conditions.

October 27, 2026

PDF Version

HENDERSON, Nev.--(BUSINESS WIRE)--Oct. 27, 2026-- Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today reported that on October 26, 2026, the Company granted inducement awards consisting of options to purchase up to 250,200 Class A Ordinary Shares (the “Options”) to five newly hired employees. These awards were approved by the Compensation Committee of the Company’s Board of Directors and granted outside the Company’s 2023 Equity Incentive Plan, as amended (the “Plan”), as inducements material to the new employees’ employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The awards are subject to the terms and conditions and other provisions set forth in the Company’s Plan and the award agreements thereunder.

The Options that were granted have an exercise price of $3.56 per Class A Ordinary Share, which is equal to the closing price of Zura’s Class A Ordinary Shares on October 26, 2026. The Options will each vest over four years, with one-fourth (1/4) of the shares subject to each Option vesting on the one-year anniversary of the applicable vesting commencement date, and the remaining shares subject to each Option shall vest in equal quarterly installments thereafter, subject to the employee’s continuous service through such vesting date.

ABOUT ZURA

Zura is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases with unmet need. Zura’s pipeline includes product candidates designed to target key mechanisms of immune system imbalance, with the goal of improving efficacy, safety, and dosing convenience for patients.

Zura’s lead product candidate, tibulizumab (ZB-106), is being evaluated in two Phase 2 clinical studies in adults: TibuSHIELD, a study in hidradenitis suppurativa (HS), and TibuSURE, a study in systemic sclerosis (SSc). A third study, NEXUS-PMR, for polymyalgia rheumatica (PMR) is planned to be initiated by year-end 2026. Additional product candidates torudokimab (ZB-880) and crebankitug (ZB-168) have completed Phase 1/1b studies and are being evaluated for their potential across a range of autoimmune and inflammatory conditions.

Prompts

Zura Bio Limited (ticker ZURA), listed in United States.

Company History

Date Change Detail
Aug 3, 2022 Renamed JATT ACQUISITION CORP → ZURA BIO LTD

ETFs Holding Zura Bio Limited

ETF Weight in ETF Shares Market value As of
AVSC 0.00% 61,673 $ 66.607K Nov 16, 2026